TLRY Stock Chart & Stats
C$5.49
C$0.23(4.19%)
At close: 4:00 PM EDT
C$5.49
C$0.23(4.19%)
Day’s Range― - ―
52-Week RangeC$5.19 - C$32.30
Previous CloseN/A
Volume429.78K
Average Volume (3M)403.29K
Market Cap
C$867.68M
Enterprise ValueC$780.77
Total Cash (Recent Filing)C$231.27M
Total Debt (Recent Filing)C$398.40M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Oct 01, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding136,203,580
10 Day Avg. Volume412,792
30 Day Avg. Volume403,287
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.38
Price to Sales (P/S)0.67
P/FCF Ratio-6.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$8.58Price Target Upside56.36% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.7
Revenue Forecast (FY)C$1.57B
Bulls Say, Bears Say
Bulls Say
Strong Liquidity & Near‑zero Net DebtTilray’s ~$235M cash balance and near‑zero net debt provide a durable liquidity cushion that reduces short‑term refinancing risk and funds integration, international expansion, and working capital needs. This balance‑sheet buffer supports execution of strategic initiatives over the next several quarters.
International Cannabis Capacity & Volume GrowthRapid international volume growth and rising facility utilization (notably Portugal) create durable scale advantages: higher GMP supply capacity, lower unit costs, and expanded medical channel access. These structural gains support sustainable top‑line and margin improvement across regulated markets over 2–6 months.
Diversified Consumer Platform: Distribution & Beverage M&ABeverage M&A and distribution scale (BrewDog, Carlsberg partnership, CC Pharma reach) diversify revenue streams beyond cannabis, expand international retail/on‑premise channels, and create cross‑sell and margin improvement opportunities. This broader consumer platform strengthens durable revenue resilience.
Bears Say
Persistent Negative Free Cash FlowTilray’s consistent negative free cash flow means the business does not self‑fund capital or acquisitions, increasing reliance on equity/debt raises. Even with cash improvements, ongoing FCF deficits constrain sustainable reinvestment and elevate refinancing and dilution risk across the next several quarters.
Continued Net LossesDespite adjusted EBITDA gains, FY2026 net loss persists, keeping returns on equity negative and limiting retained‑earnings buildup. Ongoing accounting and operating charges mean reported profitability remains elusive, reducing internal funding capacity and raising execution pressure over the medium term.
Working‑capital Strain From BrewDog IntegrationSubstantial working‑capital deployment into the BrewDog acquisition ties up cash and delays free‑cash‑flow conversion. The pre‑closing receivables and integration timing create a durable cash conversion drag, increasing short‑term financing dependence and tempering margin benefits from the deal over the coming quarters.
Tilray News
TLRY FAQ
What was Tilray’s price range in the past 12 months?
Tilray lowest stock price was C$5.19 and its highest was C$32.30 in the past 12 months.
What is Tilray’s market cap?
Tilray’s market cap is C$867.68M.
When is Tilray’s upcoming earnings report date?
Tilray’s upcoming earnings report date is Oct 01, 2026 which is in 54 days.
How were Tilray’s earnings last quarter?
Tilray released its earnings results on Jul 28, 2026. The company reported -C$0.605 earnings per share for the quarter, missing the consensus estimate of -C$0.017 by -C$0.588.
Is Tilray overvalued?
According to Wall Street analysts Tilray’s price is currently Undervalued.
Does Tilray pay dividends?
Tilray does not currently pay dividends.
What is Tilray’s EPS estimate?
Tilray’s EPS estimate is -0.23.
How many shares outstanding does Tilray have?
Tilray has 136,203,580 shares outstanding.
What happened to Tilray’s price movement after its last earnings report?
Tilray reported an EPS of -C$0.605 in its last earnings report, missing expectations of -C$0.017. Following the earnings report the stock price went down -2.465%.
Which hedge fund is a major shareholder of Tilray?
Currently, no hedge funds are holding shares in TSE:TLRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tilray Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
C$8.58 (56.36% Upside)
C$8.58 (56.36% Upside)
Blogger Sentiment
Neutral
TSE:TLRY Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth C$97.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 15.2%
Last 30 Days ▲ 15.2%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.31%
Trailing 12-Months
Company Description
Tilray
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.
TLRY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful operational progress: record revenue and adjusted EBITDA, stronger liquidity (≈$235M cash) and near-zero net debt, substantial international cannabis and distribution growth, and strategic beverage expansion through the BrewDog acquisition and the Carlsberg partnership. At the same time, challenges remain including a FY2026 net loss of $105.2M, negative adjusted free cash flow (negative $86M), international price compression (~$21M), legacy U.S. beverage headwinds, and significant working capital tied up in the BrewDog transaction. Overall the company presented a pathway to higher margins and cash generation but still faces execution and market-mix headwinds in the near term.View all TSE:TLRY earnings summariesTLRY Stock 12 Month Forecast
Average Price Target
C$8.58
▲(56.36% Upside)